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SUMMARY
Biomaterials are a new treatment strategy for cardiovascular diseases but are difficult to deliver to the heart in a safe, precise, and translatable way. We developed a method to deliver hydrogels to the epicardium through the pericardial space. Our device creates a temporary compartment for hydrogel delivery and gelation using anatomic structures. The method minimizes risk to patients from embolization, thrombotic occlusion, and arrhythmia. In pigs there were no clinically relevant acute or subacute adverse effects from pericardial hydrogel delivery, making this a translatable strategy to deliver biomaterials to the heart. (2) (3) (4) . Many of these therapies require focused delivery of the therapeutic to the heart, or even localization to particular anatomic areas, such as the peri-infarction region. Dilution of these therapeutics by systemic administration increases cost and risks off-target effects. For example, poor retention of stem cells in the heart is thought to limit efficacy in clinical trials (5) (6) (7) . The proangiogenic cytokine vascular endothelial growth factor encourages neoangiogenesis and cardiac regeneration (8) but can also accelerate tumor metastasis (9) . Efficient, targeted, and temporally appropriate delivery of therapeutics to the heart are keys to their successful translation into clinical use.
Early phase clinical trials are underway using hydrogels as therapeutic agents for cardiac repair (10) (11) (12) . Both solid patches and injectable gel materials are under investigation and may have benefits for different applications. Cardiac patches and solid materials have been tested as structural support for the heart in a clinical trial (13) and therapeutic delivery platforms in numerous preclinical studies (14) .
Their widespread use is limited by the need for surgical placement. Injectable materials with liquid or gel phases, such as decellularized matrix, alginate, and engineered hydrogels, can provide scaffolds, tactile signals, and structural support for cardiac regeneration and repair (10, 11, 15, 16) . Biomaterial gels are particularly suited to deliver stem cells to the heart and retain viable cells at the site of delivery (12, 17) . Other materials are in preclinical trial for delivery and sustained release of miRNAs, cytokines, and other therapeutics (4, 18, 19) . Whereas biocompatible materials may be beneficial for the treatment of CVD, there are no dedicated delivery methods that are safe and minimally invasive.
There are challenges inherent to delivering biomaterials to the heart. Open heart surgery, although feasible, is less desirable from a cost and patient perspective. Catheter delivery using commercially available single-lumen coronary catheters or Noga XP Cardiac Navigation System (Biosense Webster, Diegem, Belgium) cannot keep material components separate as they travel to the heart and thus cannot control the timing of material interaction and gelation. Premature gelation causes clogging within catheter lumen. Delayed gelation can lead to embolization, stroke, and failure to deliver material to targeted area. Another challenge with biomaterial delivery to the heart is the potential for inducing arrhythmias if the electrical conductivity of the material creates a substrate for a re-entrant circuits as it interdigitates between cardiomyocytes. Therefore the development of material-specific strategies is necessary for the safe, precise, and practical delivery of biomaterial to the heart. The pericardium is a novel site for therapeutic delivery that has been shown in animal studies to act as a reservoir for drug delivery to the heart (20) (21) (22) . The advent of epicardial ablations and external left atrial appendage ligation has demonstrated the feasibility of accessing a "dry" pericardial space for therapeutic purposes (23) (24) (25) . Herein we describe a minimally invasive device to deliver biomaterials to the heart by using the pericardial space as a novel anatomic site for as the Lariat device (Sentre Heart, Redwood City, California) (23, 24) . In this study, we engineered a system consisting of a hydrogel biomaterial delivery device and sheath to access the pericardial space using standard micropuncture technique ( Figure 1 ).
Device features include a shape memory core, a deployable and retractable fence that creates the lateral wall of the temporary hydrogel compartment, two separated lumens for gel components, a suction mechanism to temporarily secure the device in place, electrical sensors, and an atraumatic tip ( Figure 1 ).
As the delivery device is advanced out of the sheath, it forms a circular fence that physically isolates a 5-cm diameter area of epicardium (Supplemental Video 1). The device forms a lateral border, or fence, while the epicardium acts as a floor, and pericardium acts as a roof for the temporary gel compartment. Gentle suction further seals the
Biomaterial Delivery to the Cardiac Epicardium compartment and secures the device in place on the moving heart (Supplemental Video 1, Figure 1 ). Radiopaque markers allow precise placement over desired anatomic area using biplane fluoroscopy. Inside the device hydrogel components are kept within separate internal lumens until delivery through ports arrayed around the circular fenced area ( Figure 1C ). After gelation, the shape memory core allows retraction of the delivery device without disruption of hydrogel architecture (Supplemental Video 1).
VISUALIZATION OF HYDROGEL DELIVERY. Fourarm PEG maleimide macromer was cross-linked with dithiothreitol to form hydrogels (18) . This hydrogel system is a flexible platform for therapeutic delivery of stem cells, growth factors, and pancreatic islets in various preclinical models (16, 17, 26) . Bench studies showed that gelation occurred within 1 min after combining both components at physiological pH. We Table 1 ). Other hemodynamic features of pericardial construction, such as ventricular discordance, were not detected ( Figure 3C ). There was no periprocedural mortality. One animal was excluded from analysis because of infection unrelated to pericardial procedure but showed no hemodynamic abnormality.
FIGURE 1 Hydrogel Delivery Device Creates a Temporary Compartment for Biomaterial Gel Delivery Within the Pericardial Space
Schematic representation of lateral (A) and frontal view (B) of the device placed over the cardiac epicardium within the pericardial space.
The device forms a lateral wall for the gel compartment, whereas the pericardium and epicardium act as a natural roof and floor, respectively (A and B). Once in position, the device is secured in place by gentle suction ports (C, white arrows) to the epicardium as floor, and the pericardium as ceiling. Gel components are delivered through separate lumens and combined only after exiting the device (B and C, asterisk) through ports arrayed around fence (C, black arrows). Electrical sensors (C, arrowhead) allow precise placement over areas of electrical abnormalities, such as infarcts. See Supplemental Video 1.
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INFLAMMATORY EFFECTS OF PERICARDIAL PROCEDURE
AND GEL DELIVERY. Pericarditis is a well-known consequence of pericardial procedures and we evaluated animals for signs of systemic or local inflammation (23-25). We measured white blood cell count, differential, creatinine, and liver function tests, which remained normal in all animals (Supplemental Table 2 ). Total white blood cell count decreased in 6 of 8 animals (mean decrease by 2.1 Â 10 9 AE Table 2 ). Neutrophil and lymphocyte counts were also stable (Supplemental Table 2 ). trypan blue-labeled gel was delivered with the device to the posterior wall and gelled within the temporary compartment created by the device, epicardium, and pericardium. Sixty minutes after device removal, the gel remained localized over delivery location. Garcia et al. We have shown a lack of significant hemodynamic and inflammatory effects of pericardial gel delivery.
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Triggering inflammation in the pericardium is of especially great concern because this area is prone to refractory symptoms and chronic pathologic consequences. Inflammation of the pericardium can cause hemodynamically significant pericardial effusions or thickening and fibrosis of the pericardium leading to cardiac constriction. We undertook careful histologic and hemodynamic studies to assess for these changes. In our study invasive measurements of intracardiac pressures showed stable filling pressures over 4 to 6 weeks. This suggests that pericardial biomaterial delivery will not have negative hemodynamic effects. Histology did show some inflammation localized to the parietal pericardium overlying the pericardial puncture site, whereas the white blood cell count and differential remained stable (Supplemental Table 2 ). The increased cellularity was localized to a 1-cm 2 area that was the site of pericardial puncture and was likely the result of the puncture injury and healing. Other areas of the pericardium and the myocardium appeared normal.
STUDY LIMITATIONS. For other pericardial procedures, such as the Lariat device, prophylactic anti-inflammatory medications, such as colchicine, are commonly used. Although reported incidence of pericarditis is low, most patients are prophylactically treated with anti-inflammatory agents, specifically colchicine (28) . In one study of the Lariat device, the reported incidence of pericarditis was 5% but 54% of patients were treated with colchicine (23, 28 ). In the current study, we chose to treat our animals with colchicine based on a preliminary study that showed significant pericardial inflammation when antiinflammatory agents were not used. 
CONCLUSIONS
We have developed a novel method for delivering biomaterial gels to the heart through the pericardial space. Our platform can be used with many types of gels and is a new treatment strategy for CVD that may Biomaterial Delivery to the Cardiac Epicardium O C T O B E R 2 0 1 7 : 6 0 1 -9
